SAGE Therapeutics (SAGE) said Wednesday that its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.
The company said that the study was unable to demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo and as a result, it does not plan further development.
Sage Therapeutics' share price fell more than 8% in recent premarket activity on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.